High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes

Bone Research

Volumn 2, Issue , 2015, Pages

  Brommage, Robert ^a   Liu, Jeff ^a   Hansen, Gwenn M ^a   Kirkpatrick, Laura L ^a   Potter, David G ^a   Sands, Arthur T ^a   Zambrowicz, Brian ^a   Powell, David R ^a   Vogel, Peter ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84923897116     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/boneres.2014.34     Document Type: Article

References (331)

1. Moore MW. High-throughput gene knockouts and phenotyping in mice. Ernst Schering Res Found Workshop 2005; 50: 27-44.
2. International Mouse Knockout Consortium, Collins FS, Rossant J, Wurst W. A mouse for all reasons. Cell 2007; 128: 9-13.
3. Collins FS, Finnell RH, Rossant J. Wurst W. A new partner for the International Knockout Mouse Consortium. Cell 2007; 129: 235.
4. Bradley A, Anastassiadis K, AyadiAet al. The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm Genome 2012; 23: 580-586.
5. Schofield PN, Hoehndorf R, Gkoutos GV. Mouse genetic and phenotypic resources for human genetics. Hum Mutat 2012; 33: 826-836.
6. Ramirez-Solis R, Ryder E, Houghton R, White, JK, Bottomley J. Largescale mouse knockouts and phenotypes. Wiley Interdiscip Rev Syst Biol Med 2012; 4: 547-563.
7. Friddle CJ, Abuin A, Ramirez-Solis R et al. High-throughput mouse knockouts provide a functional analysis of the genome. Cold Spring Harb Symp Quant Biol 2003; 68: 311-315.
8. Hansen GM,Markesich DC, BurnettMB et al. Large-scale gene trapping in C57BL/6N mouse embryonic stem cells. Genome Res 2008; 18: 1670-1679.
9. Clark HF, Gurney AL, Abaya E et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res 2003; 13: 2265-2270.
10. Tang T, Li L, Tang J et al. A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol 2010; 28: 749-775.
11. Brommage R, Desai U, Revelli JP et al. High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity (Silver Spring) 2008; 16: 2362-2367.
12. Brown SD, Moore MW. The International Mouse Phenotyping Consortium: past and future perspectives on mouse phenotyping. Mammalian Genome 2012; 23: 632-640.
13. Koscielny G, Yaikhom G, Iyer V et al. The International Mouse Phenotyping Consortium Web Portal, a unified point of access for knockout mice and related phenotyping data. Nucleic Acids Res 2014; 42: D802-D809.
14. Ayadi A, Birling MC, Bottomley J et al. Mouse large-scale phenotyping initiatives: overview of the European MouseDisease Clinic (EUMODIC) and of the Wellcome Trust Sanger Institute Mouse Genetics Project. Mamm Genome 2012; 23: 600-610.
15. Beckers J, Wurst W, de Angelis MH. Towards better mouse models: enhanced genotypes, systemic phenotyping and envirotype modelling. Nat Rev Genet 2009; 10: 371-380.
16. Brown MJ, Murray KA. Phenotyping of genetically engineered mice: humane, ethical, environmental, and husbandry issues. ILAR J 2006; 47: 118-123.
17. Fuchs H, Lisse T, Hans W et al. Phenotypic characterization of mouse models for bone-related diseases in the German Mouse Clinic. J Musculoskelet Neuronal Interact 2008; 8: 13-14.
18. Fuchs H, Gailus-Durner V, Neschen S et al. Innovations in phenotyping of mouse models in the German Mouse Clinic. Mamm Genome 2012; 23: 611-622.
19. Justice MJ. Removing the cloak of invisibility: phenotyping the mouse. Dis Models Mech 2008; 1: 109-112.
20. Murray KA. Issues to consider when phenotyping mutant mouse models. Lab Anim (NY) 2002; 31: 25-29.
21. Schofield PN, Dubus P, Klein L et al. Pathology of the laboratory mouse: an International Workshop on Challenges for High Throughput Phenotyping. Toxicol Pathol 2011; 39: 559-562.
22. Schofield PN, Vogel P, Gkoutos GV, Sundberg JP. Exploring the elephant: histopathology in high-throughput phenotyping of mutant mice. Dis Models Mech 2012; 5: 19-25.
23. Zeiss CJ, Ward JM, Allore HG. Designing phenotyping studies for genetically engineered mice. Vet Pathol 2012; 49: 24-31.
24. Bassett JH, Gogakos A, White JK et al. Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. PLoS Genet 2012; 8: e1002858.
25. White JK, Gerdin AK, Karp NA et al. Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell 2013; 154: 452-464.
26. Iwaniec UT, Wronski TJ, Liu J et al. PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res 2007; 22: 394-402.
27. Brommage R, Liu J, Suwanichkul A, Powell DR. High bone mass in sclerostin-deficient knockout mice. J Musculoskelet Neuronal Interact 2006; 6: 392.
28. Brommage R, Liu J, Revelli JP, Kirkpatrick LL, Powell DR. Gene knockouts of Wnt10b and Wnt16 in mice result in low bone mass. Bone 2007; 40(Suppl 2): S187.
29. Brommage R, Liu J, Bright D et al. Elevated bone mass in mice treated with anti-Dickkopf-1 neutralizing antibodies. J Bone Miner Res 2010; 25(Suppl 1): S81.
30. Brommage R, Liu J, Lee E. Elevated trabecular bone mass with reduced cortical bone thickness in sFRP4 knockout mice. J Bone Miner Res 2009; 24(Suppl 1): S82.
31. Walke DW, Han C, Shaw J, Wann E, Zambrowicz B, Sands A. In vivo drug target discovery: identifying the best targets from the genome. Curr Opin Biotechnol 2001; 12: 626-631.
32. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov 2003; 2: 38-51.
33. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 2003; 3: 563-570.
34. Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today 2005; 10: 1607-1610.
35. Plewczynski D, Rychlewski L. Meta-basic estimates the size of druggable human genome. J Mol Model 2009; 15: 695-699.
36. Nieman BJ, Blank MC, Roman BB, Henkelman RM, Millen KJ. If the skull fits: magnetic resonance imaging and microcomputed tomography for combined analysis of brain and skull phenotypes in the mouse. Physiol Genomics 2012; 44: 992-1002.
37. Medina-Gomez C, Kemp JP, Estrada K et al. Meta-analysis of genomewide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet 2012; 8: e1002718.
38. Zheng HF, Tobias JH, Duncan E et al. WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet 2012; 8: e1002745.
39. Xing W, Liu J, Cheng S, Vogel P, Mohan S, Brommage R. Targeted disruption of leucine-rich repeat kinase 1 but not leucine-rich repeat kinase 2 in mice causes severe osteopetrosis. J Bone Miner Res 2013; 28: 1962-1974.
40. Linares GR, Brommage R, Powell DRet al. Claudin 18 is a novel negative regulator of bone resorption and osteoclast differentiation. J Bone Miner Res 2012; 27: 1553-1565.
41. Tagliabracci VS, Pinna LA, Dixon JE. Secreted protein kinases. Trends Biochem Sci 2013; 38: 121-130.
42. Vogel P,Hansen GM, ReadRWet al. Amelogenesis imperfecta and other biomineralization defects in Fam20a and Fam20c null mice. Vet Pathol 2012; 49: 998-1017.
43. Hla T, Dannenberg AJ. Sphingolipid signaling in metabolic disorders. Cell Metab 2012; 16: 420-434.
44. Lotinun S, Kiviranta R, Matsubara T et al. Osteoclast-specific cathepsinK deletion stimulates S1P-dependent bone formation. J Clin Invest 2013; 123: 666-681.
45. Vogel P,Donoviel MS, Read R et al. Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PloS One 2009; 4: e4112.
46. Wattler S, Kelly M, NehlsM.Construction of gene targeting vectors from lambda KOS genomic libraries. Biotechniques 1999; 26: 1150-1156, 1158, 1160.
47. Zambrowicz BP, Holt KH, Walke W, Kirkpatrick LL, Eberhart DE. Generation of transgenic animals. In: Metcalf B, Dillon S (ed.), Target validation in drug discovery. New York: Elsevier Academic Press, 2006: 3-25.
48. Abuin A, Hansen GM, Zambrowicz B. Gene trap mutagenesis. Handb Exp Pharmacol 2007; 178: 129-147.
49. Atasoy D, Schoch S, Ho A et al. Deletion of CASK in mice is lethal and impairs synaptic function. Proc Natl Acad Sci USA 2007; 104: 2525-2530.
50. Gale NW, Dominguez MG, Noguera I et al. Haploinsufficiency of deltalike 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA 2004; 101: 15949-15954.
51. Brommage R. Validation and calibration of DEXA body composition in mice. Am J Physiol Endocrinol Metab 2003; 285: E454-E459.
52. Rissanen JP, Suominen MI, Peng Z et al. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcified Tissue Int 2008; 82: 155-161.
53. Anderson JM, van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol 2009; 1: a002584.
54. Wongdee K, Pandaranandaka J, Teerapornpuntakit J et al. Osteoblasts express claudins and tight junction-associated proteins. Histochem Cell Biol 2008; 130: 79-90.
55. Doty SB. Morphological evidence of gap junctions between bone cells. Calcif Tissue Int 1981; 33: 509-512.
56. Hayashi D, Tamura A, Tanaka H et al. Deficiency of claudin-18 causes paracellular H1 leakage, up-regulation of interleukin-1beta, and atrophic gastritis in mice. Gastroenterology 2012; 142: 292-304.
57. Alshbool FZ, Alarcon C, Wergedal J, Mohan S. A high-calcium diet failed to rescue an osteopenia phenotype in claudin-18 knockout mice. Physiol Rep 2014; 2: e00200.
58. Wang X, Wang S, Li C et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet 2012; 8: e1002708.
59. Simpson MA, Hsu R, Keir LS et al. Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development. Am J Hum Genet 2007; 81: 906-912.
60. Tagliabracci VS, Engel JL, Wen J et al. Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science 2012; 336: 1150-1153.
61. Ishikawa HO, Xu A, Ogura E, Manning G, Irvine KD. The Raine syndrome protein FAM20C is a Golgi kinase that phosphorylates biomineralization proteins. PLoS One 2012; 7: e42988.
62. Tagliabracci VS, Engel JL, Wiley SE et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 2014; 111: 5520-5525.
63. Gong Y, Slee RB, Fukai N et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107: 513-523.
64. Kato M, Patel MS, Levasseur R et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002; 157: 303-314.
65. Holmen SL, Giambernardi TA, Zylstra CR et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 2004; 19: 2033-2040.
66. Li X, Ominsky MS, Niu QT et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23: 860-869.
67. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010; 25: 178-189.
68. Sawakami K, Robling AG, Ai M et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 2006; 281: 23698-23711.
69. Arantes HP, Barros, ER, Kunii I, Bilezikian JP, Lazaretti-Castro M. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. J Bone Miner Res 2011; 26: 2823-2826.
70. Cui Y, Niziolek PJ, MacDonald BT et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011; 17: 684-691.
71. Yadav VK, Ryu JH, Suda N et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008; 135: 825-837.
72. Xu Q, Wang Y, Dabdoub A et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligandreceptor pair. Cell 2004; 116: 883-895.
73. Ke J, Harikumar KG, Erice C et al. Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5/6 complex. Genes Dev 2013; 27: 2305-2319.
74. Lobov IB, Rao S, Carroll TJ et al. WNT7bmediates macrophage-induced programmed cell death in patterning of the vasculature. Nature 2005; 437: 417-421.
75. Xia CH, Yablonka-Reuveni Z, Gong X. LRP5 is required for vascular development in deeper layers of the retina. PloS One 2010; 5: e11676.
76. Paes KT, Wang E, Henze K et al. Frizzled 4 is required for retinal angiogenesis and maintenance of the blood-retina barrier. Invest Ophthalmol Vis Sci 2011; 52: 6452-6461.
77. Marin I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol 2006; 23: 2423-2433.
78. Baptista MA, Dave KD, Sheth NP et al. A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. Dis Model Mech 2013; 6: 1316-1324.
79. Kim BJ, Koh JM, Lee SY et al. Plasma sphingosine 1-phosphate levels and the risk of vertebral fracture in postmenopausal women. J Clin Endocrinol Metab 2012; 97: 3807-3814.
80. Pederson L, RuanM,Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA 2008; 105: 20764-20769.
81. Bagdanoff JT, Donoviel MS, Nouraldeen A et al. Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem 2009; 52: 3941-3953.
82. Bagdanoff JT, Donoviel MS, Nouraldeen A et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem 2010; 53: 8650-8662.
83. Kesavan C, Mohan S, Brommage R, Wergedal J. Wnt16 is an important regulator of bone size and the periosteal bone formation response to mechanical loading. J Bone Miner Res 2013; 28(Suppl 1): S100.
84. Skrtic SM et al. WNT16 is a novel osteoblast-derived paracrine regulator of osteoclastogenesis, cortical bone mass and fracture susceptibility. J Bone Miner Res 2013; 28(Suppl 1): S39.
85. Motyl KJ, Raetz M, Tekalur SA, Schwartz RC, McCabe LR. CCAAT/enhancer binding protein beta-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption. Am J Physiol Regul Integr Comp Physiol 2011; 300: R1250-R1260.
86. Staiger J, Lueben MJ, Berrigan D et al. C/EBPbeta regulates body composition, energy balance-related hormones and tumor growth. Carcinogenesis 2009; 30: 832-840.
87. Tominaga H, Maeda S, Hayashi M et al. CCAAT/enhancer-binding protein beta promotes osteoblast differentiation by enhancing Runx2 activity with ATF4. Mol Biol Cell 2008; 19: 5373-5386.
88. Zanotti S, Stadmeyer L, Smerdel-Ramoya A, Durant, D, Canalis E. Misexpression of CCAAT/enhancer binding protein beta causes osteopenia. J Endocrinol 2009; 201: 263-274.
89. Morello R, Bertin TK, Chen Y et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006; 127: 291-304.
90. Baldridge D, Lennington J, Weis M et al. Generalized connective tissue disease in Crtap-/-mouse. PLoS One 2010; 5: e10560.
91. Weber G, Rabbiosi S, Zamproni I, Fugazzola L. Genetic defects of hydrogen peroxide generation in the thyroid gland. J Endocrinol Invest 2013; 36: 261-266.
92. Johnson KR, Marden CC, Ward-Bailey P, Gagnon LH, Bronson RT, Donahue LR. Congenital hypothyroidism, dwarfism, and hearing impairment caused by a missense mutation in the mouse dual oxidase 2 gene, Duox2. Mol Endocrinol 2007; 21: 1593-1602.
93. Grasberger H, de Deken X,Mayo OB et al. Mice deficient in dual oxidase maturation factors are severely hypothyroid. Mol Endocrinol 2012; 26: 481-492.
94. Xing W, Govoni KE, Donahue LR et al. Genetic evidence that thyroid hormone is indispensable for prepubertal insulin-like growth factor-I expression and bone acquisition in mice. J Bone Miner Res 2012; 27: 1067-1079.
95. Donko A, Ruisanchez E, Orient A et al. Urothelial cells produce hydrogen peroxide through the activation of Duox1. Free Radic Biol Med 2010; 49: 2040-2048.
96. Mackenzie NC, Zhu D, Milne EM et al. Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice. PloS One 2012; 7: e32177.
97. Koshizuka Y, Ikegawa S, Sano M, Nakamura K, Nakamura Y. Isolation of novel mouse genes associated with ectopic ossification by differential display method using ttw, a mouse model for ectopic ossification. Cytogenet Cell Genet 2001; 94: 163-168.
98. Babij P, Roudier M, Graves T et al. New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification. J Bone Miner Res 2009; 24: 1552-1564.
99. Li Q, Guo H, ChouDW,Berndt A, Sundberg JP,Uitto J. Mutant Enpp1asj mice as a model for generalized arterial calcification of infancy. Dis Model Mech 2013; 6: 1227-1235.
100. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92: 131-155.
101. Bhattacharyya N, Chong WH, Gafni RI, Collins MT. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab 2012; 23: 610-618.
102. Yamashita T, Yoshitake H, Tsuji K, Kawaguchi N, Nabeshima Y, Noda M. Retardation in bone resorption after bone marrow ablation in klotho mutant mice. Endocrinology 2000; 141: 438-445.
103. Yuan Q, Sato T, Densmore M et al. Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/-mice. PLoS Genet 2012; 8: e1002726.
104. Ellwanger K, Saito H, Clément-Lacroix P et al. Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density. Mol Cell Biol 2008; 28: 4875-4882.
105. Schulze J, Seitz S, SaitoHet al. Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. PLoS One 2010; 5: e10309.
106. Zhou Z, Xie J, Lee D et al. Neogenin regulation of BMP-induced canonical Smad signaling and endochondral bone formation. Dev Cell 2010; 19: 90-102.
107. Contie S, Voorzanger-Rousselot N, Litvin J et al. Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int 2010; 87: 341-350.
108. Horiuchi K, Amizuka N, Takeshita S et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J BoneMiner Res 1999; 14: 1239-1249.
109. Bonnet N, Standley KN, Bianchi EN et al. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem 2009; 284: 35939-35950.
110. Rios H, Koushik SV, Wang H et al. Periostin nullmice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 2005; 25: 11131-11144.
111. Bonnet N, Gineyts E, Ammann P, Conway SJ, Garnero P, Ferrari S. Periostin deficiency increases bone damage and impairs injury response to fatigue loading in adult mice. PLoS One 2013; 8: e78347.
112. Fukada T, Civic N, Furuichi T et al. The zinc transporter SLC39A13/ZIP13 is required for connective tissue development; its involvement in BMP/TGF-beta signaling pathways. PLoS One 2008; 3: e3642.
113. Giunta C, Elçioglu NH, Albrecht B et al. Spondylocheiro dysplastic form of the Ehlers-Danlos syndrome - an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13. Am J Hum Genet 2008; 82: 1290-1305.
114. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568.
115. Chalhoub N, Benachenhou N, Rajapurohitam V et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med 2003; 9: 399-406.
116. Pata M, Heraud C, Vacher J. OSTM1 bone defect reveals an intercellular hematopoietic crosstalk. J Biol Chem 2008; 283: 30522-30530.
117. Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC. ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 2006; 440: 220-223.
118. Chusho H, Tamura N, Ogawa Y et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 2001; 98: 4016-4021.
119. Kondo E, Yasoda A, Tsuji T et al. Skeletal analysis of the long bone abnormality (lbab/lbab) mouse, a novel chondrodysplastic C-type natriuretic peptide mutant. Calcif Tissue Int 2012; 90: 307-318.
120. Tsuji T, Kunieda T. A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. J Biol Chem 2005; 280: 14288-14292.
121. Sogawa C, Tsuji T, Shinkai Y, Katayama K, Kunieda T. Short-limbed dwarfism: slwis a new allele of Npr2 causing chondrodysplasia. J Hered 2007; 98: 575-580.
122. Bartels CF, Bükülmez H, Padayatti P et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 2004; 75: 27-34.
123. MiuraK,Namba N, FujiwaraMet al.Anovergrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 gene. PLoS One 2012; 7: e42180.
124. Dauphinee SM, Eva MM, Yuki KE et al. Characterization of two ENUinduced mutations affecting mouse skeletal morphology. G3 (Bethesda) 2013; 3: 1753-1758.
125. Moffatt P, Thomas G, Sellin K et al. Osteocrin is a specific ligand of the natriuretic peptide clearance receptor that modulates bone growth. J Biol Chem 2007; 282: 36454-36462.
126. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
127. Kubota T, Michigami T, Sakaguchi N et al. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J Bone Miner Res 2008; 23: 1661-1671.
128. Mani A, Radhakrishnan J,Wang H et al. LRP6 mutation in a familywith early coronary disease and metabolic risk factors. Science 2007; 315: 1278-1282.
129. Babij P, Zhao W, Small C et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003; 18: 960-974.
130. Boyden LM, Mao J, Belsky J et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002; 346: 1513-1521.
131. MacDonald BT, Joiner DM, Oyserman SM et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 2007; 41: 331-339.
132. Morvan F, Boulukos K, Clément-Lacroix P et al. Deletion of a single allele of theDkk1 gene leads to an increase in bone formation and bonemass. J Bone Miner Res 2006; 21: 934-945.
133. Morse A, Frank C, Kelly NH et al. Sclerostin null and dickkopf-1 null mice show an increased response to mechanical loading. Proc Orthop Res Soc Annu Meet 2014; Poster Number 0567.
134. McDonald M, Morse M, Baldock P et al. Homozygous deletion of Dickkopf1 results in a high bone mass phenotype. J Bone Miner Res 2010; 25(Suppl 1): S23-S24.
135. Li J, Sarosi I, Cattley RC et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006; 39: 754-766.
136. Fulciniti M, Tassone P, Hideshima T et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371-379.
137. Glantschnig H, Hampton RA, Lu P et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 2010; 285: 40135-40147.
138. Glantschnig H, Scott K, Hampton R et al. A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primatemodels of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 2011; 338: 568-578.
139. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33: 747-783.
140. Pozzi S, Fulciniti M, YanHet al. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone 2013; 53: 487-496.
141. Zhou F, Meng S, Song H, Claret FX. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev 2013; 27: 261-267.
142. FanW, et al. Differential impact of Dkk1 neutralizing antibodies on Wnt signaling and bone mineral density. J Bone Miner Res 2011; 26(Suppl 1): S117.
143. Li X, Grisanti M, Fan W et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 2011; 26: 2610-2621.
144. Mukhopadhyay M, Gorivodsky M, Shtrom S et al. Dkk2 plays an essential role in the corneal fate of the ocular surface epithelium. Development 2006; 133: 2149-2154.
145. Gage PJ, Qian M, Wu D, Rosenberg KI. The canonical Wnt signaling antagonist DKK2 is an essential effector of PITX2 function during normal eye development. Dev Biol 2008; 317: 310-324.
146. Li X, Liu P, Liu W et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 2005; 37: 945-952.
147. Barrantes Idel B, Montero-Pedrazuela A, Guadaño-Ferraz A, et al. Generation and characterization of dickkopf3 mutant mice. Mol Cell Biol 2006; 26: 2317-2326.
148. Ouchi N, Higuchi A, Ohashi K et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010; 329: 454-457.
149. Mori H, Prestwich TC, Reid MA et al. Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition. J Clin Invest 2012; 122: 2405-2416.
150. Cox S, Smith L, Bogani D, Cheeseman M, Siggers P, Greenfield A. Sexually dimorphic expression of secreted frizzled-related (SFRP) genes in the developing mouse Mullerian duct. Mol Reprod Dev 2006; 73: 1008-1016.
151. Satoh W, Gotoh T, Tsunematsu Y, Aizawa S, ShimonoA. Sfrp1 and Sfrp2 regulate anteroposterior axis elongation and somite segmentation during mouse embryogenesis. Development 2006; 133: 989-999.
152. Morello R, Bertin TK, Schlaubitz S et al. Brachy-syndactyly caused by loss of Sfrp2 function. J Cell Physiol 2008; 217: 127-137.
153. Yao W, Cheng Z, Shahnazari M, Dai W, Johnson ML, Lane NE. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res 2010; 25: 190-199.
154. Bodine PV, Zhao W, Kharode YP et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004; 18: 1222-1237.
155. Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol 2007; 210: 352-357.
156. Joesting MS, Cheever TR, Volzing KG et al. Secreted frizzled related protein 1 is a paracrine modulator of epithelial branching morphogenesis, proliferation, and secretory gene expression in the prostate. Dev Biol 2008; 317: 161-173.
157. Gauger KJ, Bassa LM, Henchey EM et al. Mice deficient in sfrp1 exhibit increased adiposity, dysregulated glucose metabolism, and enhanced macrophage infiltration. PloS One 2013; 8: e78320.
158. Lories RJ, Peeters J, Bakker A et al. Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice. Arthritis Rheum 2007; 56: 4095-4103.
159. Baker-Lepain JC, Lynch JA, Parimi N et al. Variant alleles of the Wnt antagonist FRZB are determinants of hip shape and modify the relationship between hip shape and osteoarthritis. Arthritis Rheum 2012; 64: 1457-1465.
160. Saito H, Wissmann C, Suzuki H et al. Deletion of the Wnt signaling antagonist Secreted frizzled related protein 4 (sFRP4) in mice induces opposite bone formation phenotypes in trabecular and cortical bone. J Bone Miner Res 2008; 23(Suppl 1) : S3.
161. Kao R, Louie A, Lu WD, Nissenson R. Differential regulation of cortical and trabecular bone by Secreted frizzled-related protein 4 (Sfrp4). J Bone Miner Res 2010; 25(Suppl 1): S425.
162. Saito H, et al. sFrp4 differentially regulates trabecular and cortical bone mass via canonical Wnt and Ror2-BMP-sclerostin signaling, respectively. J Bone Miner Res 2011; 26(Suppl 1): S50.
163. Kansara M, Tsang M, Kodjabachian L et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009; 119: 837-851.
164. Schaniel C, Sirabella D, Qiu J, Niu X, Lemischka IR, Moore KA. Wntinhibitory factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cells. Blood 2011; 118: 2420-2429.
165. Cawthorn WP, Bree AJ, Yao Y et al. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenindependent mechanism. Bone 2012; 50: 477-489.
166. Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 2009; 85: 538-545.
167. Wend P, Wend K, Krum SA,Miranda-Carboni GA. The role of WNT10B in physiology and disease. Acta Physiol (Oxf) 2012; 204: 34-51.
168. Stevens JR, Miranda-Carboni GA, Singer MA, Brugger SM, Lyons KM, Lane TF. Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res 2010; 25: 2138-2147.
169. Bennett CN, Longo KA, Wright WS et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005; 102: 3324-3329.
170. Bennett CN, Ouyang H, Ma YL et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 2007; 22: 1924-1932.
171. Terauchi M, Li JY, Bedi B et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 2009; 10: 229-240.
172. Kukita T, Wada N, Kukita A et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 2004; 200: 941-946.
173. Yagi M, Miyamoto T, Sawatani Y et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005; 202: 345-351.
174. Miyamoto T. Regulators of osteoclast differentiation and cell-cell fusion. Keio J Med 2011; 60: 101-105.
175. Kollmann K, Pestka JM, Kühn SC et al. Decreased bone formation and increased osteoclastogenesis cause bone loss in mucolipidosis II. EMBO Mol Med 2013; 5: 1871-1886.
176. Gelfman CM, Vogel P, IssaTMet al. Mice lacking alpha/beta subunits of GlcNAc-1-phosphotransferase exhibit growth retardation, retinal degeneration, and secretory cell lesions. Invest Ophthalmol Vis Sci 2007; 48: 5221-5228.
177. Vogel P, Payne BJ, Read R et al. Comparative pathology of murine mucolipidosis types II and IIIC. Vet Pathol 2009; 46: 313-324.
178. Colledge WH. Transgenic mouse models to study Gpr54/kisspeptin physiology. Peptides 2009; 30: 34-41.
179. Dungan Lemko HM, Elias CF. Kiss of the mutant mouse: how genetically altered mice advanced our understanding of kisspeptin's role in reproductive physiology. Endocrinology 2012; 153: 5119-5129.
180. Brommage R, Qian N, Vogel P et al. Mice failing to undergo puberty due to targeted inactivation of the GPR54 gene exhibit alterations in body composition and reduced bonemass. J BoneMiner Res 2004; 19(Suppl 1): S93.
181. Hamrick MW, Samaddar T, Pennington C, McCormick J. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J Bone Miner Res 2006; 21: 477-483.
182. Elkasrawy MN, HamrickMW.Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 2010; 10: 56-63.
183. Mitchell AD, Wall RJ. In vivo evaluation of changes in body composition of transgenic mice expressing the myostatin pro domain using dual energy X-ray absorptiometry. Growth Dev Aging 2007; 70: 25-37.
184. Inoue K, Matsuda K, Itoh M et al. Osteopenia and male-specific sudden cardiac death in mice lacking a zinc transporter gene, Znt5. Hum Mol Genet 2002; 11: 1775-1784.
185. Dacquin R, Davey RA, Laplace C et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 2004; 164: 509-514.
186. Davey RA, Turner AG, McManus JF et al. Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J BoneMiner Res 2008; 23: 1182-1193.
187. Gazzerro E, Smerdel-Ramoya A, Zanotti S et al. Conditional deletion of gremlin causes a transient increase in bone formation and bone mass. J Biol Chem 2007; 282: 31549-31557.
188. Canalis E, Parker K, Zanotti S. Gremlin1 is required for skeletal development and postnatal skeletal homeostasis. J Cell Physiol 2012; 227: 269-277.
189. Cheung CL, Lau KS, Sham PC, Tan KC, Kung AW. Genetic variants in GREM2 are associated with bone mineral density in a southern Chinese population. J Clin Endocrinol Metab 2013; 98: E1557-E1561.
190. Paternoster L, Lorentzon M, Lehtimäki T et al. Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. PLoS Genet 2013; 9: e1003247.
191. Zuniga E, Rippen M, Alexander C, Schilling TF, Crump JG. Gremlin 2 regulates distinct roles of BMP and Endothelin 1 signaling in dorsoventral patterning of the facial skeleton. Development 2011; 138: 5147-5156.
192. Vogel P, Liu J, Platt KA et al. Malformation of incisor teeth in Grem2-/-mice. Vet Pathol 2014; [Epub ahead of print].
193. Poli V, Balena R, Fattori E et al. Interleukin-6 deficientmice are protected from bone loss caused by estrogen depletion. EMBO J 1994; 13: 1189-1196.
194. Dai J, Lin D, Zhang J et al. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J Clin Invest 2000; 106: 887-895.
195. Jilka RL, Hangoc G, Girasole G et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88-91.
196. Kimble RB, Bain S, Pacifici R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 1997; 12: 935-941.
197. O'Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS,Manolagas SC. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 2005; 289: E784-E793.
198. del Fattore A, Cappariello A, CapulliMet al. An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6. Osteoporos Int 2014; 25: 681-692.
199. Grey A, Mitnick MA, Masiukiewicz U et al. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 1999; 140: 4683-4690.
200. Xu J, Song P, Nakamura S et al. Deletion of the chloride transporter slc26a7 causes distal renal tubular acidosis and impairs gastric acid secretion. J Biol Chem 2009; 284: 29470-29479.
201. Spitzweg C, Morris JC. Genetics and phenomics of hypothyroidism and goiter due to NIS mutations. Mol Cell Endocrinol 2010; 322: 56-63.
202. Everett LA, Belyantseva IA, Noben-Trauth K et al. Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome. Hum Mol Genet 2001; 10: 153-161.
203. Kim KX, Sanneman JD, Kim HM et al. Slc26a7 chloride channel activity and localization in mouse Reissner's membrane epithelium. PLoS One 2014; 9: e97191.
204. Khadeer MA, Sahu SN, BaiG, Abdulla S, GuptaA. Expression of the zinc transporter ZIP1 in osteoclasts. Bone 2005; 37: 296-304.
205. Kambe T, Geiser J, Lahner B, Salt DE, Andrews GK. Slc39a1 to 3 (subfamily II) Zip genes in mice have unique cell-specific functions during adaptation to zinc deficiency. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1474-R1481.
206. Gilmour DT, Lyon GJ, Carlton MB et al. Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO J 1998; 17: 1860-1870.
207. Norose K, Clark JI, Syed NA et al. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 1998; 39: 2674-2680.
208. Bradshaw AD, Graves DC, Motamed K, Sage EH. SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proc Natl Acad Sci USA 2003; 100: 6045-6050.
209. Gruber HE, Sage EH, Norton HJ et al. Targeted deletion of the SPARC gene accelerates disc degeneration in the aging mouse. J Histochem Cytochem 2005; 53: 1131-1138.
210. Delany AM, AmlingM, PriemelMet al. Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest 2000; 105: 1325.
211. Boskey AL, Moore DJ, Amling M, Canalis E, Delany AM. Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wildtype controls. J Bone Miner Res 2003; 18: 1005-1011.
212. Mansergh FC, Wells T, Elford C et al. Osteopenia in Sparc (osteonectin)-deficient mice: characterization of phenotypic determinants of femoral strength and changes in gene expression. Physiol Genomics 2007; 32: 64-73.
213. Barros NM, Hoac B, Neves RL et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res 2013; 28: 688-699.
214. Ishijima M, Rittling SR, Yamashita T et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 2001; 193: 399-404.
215. Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 2002; 71: 145-154.
216. OnoN,Nakashima K, Rittling SR et al. Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J Biol Chem 2008; 283: 19400-19409.
217. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 1999; 96: 8156-8160.
218. Harmey D, Johnson KA, Zelken J et al. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res 2006; 21: 1377-1386.
219. Malaval L, Wade-Guéye NM, BoudiffaMet al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 2008; 205: 1145-1153.
220. Thurner PJ, Chen CG, Ionova-Martin S et al. Osteopontin deficiency increases bone fragility but preserves bonemass. Bone 2010; 46: 1564-1573.
221. Novack DV, Faccio R. Osteoclast motility: putting the brakes on bone resorption. Ageing Res Rev 2011; 10: 54-61.
222. Sakai D, Tong HS, Minkin C. Osteoclast molecular phenotyping by random cDNA sequencing. Bone 1995; 17: 111-119.
223. Shuang F, Sun Y, Yang HH et al. Destrin deletion enhances the bone loss in hindlimb suspended mice. Eur J Appl Physiol 2013; 113: 403-410.
224. Niwa R, Nagata-Ohashi K, Takeichi M, Mizuno K, Uemura T. Control of actin reorganization by Slingshot, a family of phosphatases that dephosphorylate ADF/cofilin. Cell 2002; 108: 233-246.
225. Blangy A, Touaitahuata H, Cres G, Pawlak G. Cofilin activation during podosome belt formation in osteoclasts. PLoS One 2012; 7: e45909.
226. Mizuno K. Signaling mechanisms and functional roles of cofilin phosphorylation and dephosphorylation. Cell Signal 2013; 25: 457-469.
227. Meng Y, Zhang Y, Tregoubov V et al. Abnormal spine morphology and enhanced LTP in LIMK-1 knockout mice. Neuron 2002; 35: 121-133.
228. Kawano T, Zhu M, Troiano N et al. LIM kinase 1 deficient mice have reduced bone mass. Bone 2013; 52: 70-82.
229. Collette NM, Yee CS, Murugesh D et al. Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner. Dev Biol 2013; 383: 90-105.
230. Ellies DL, Economou A, Viviano B et al. Wise regulates bone deposition through genetic interactions with Lrp5. PLoS One 2014; 9: e96257.
231. Person AD, Beiraghi S, Sieben CM et al. WNT5A mutations in patients with autosomal dominant Robinow syndrome. Dev Dyn 2010; 239: 327-337.
232. Yamaguchi TP, Bradley A, McMahon AP, Jones S. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 1999; 126: 1211-1223.
233. Lin M, Li L, Liu C et al. Wnt5a regulates growth, patterning, and odontoblast differentiation of developing mouse tooth. Dev Dyn 2011; 240: 432-440.
234. Yang Y, Topol L, Lee H, Wu J. Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development 2003; 130: 1003-1015.
235. MaedaK,KobayashiY, UdagawaNet al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012; 18: 405-412.
236. Agalliu D, Takada S, Agalliu I, McMahon AP, Jessell TM.Motor neurons with axial muscle projections specified by Wnt4/5 signaling. Neuron 2009; 61: 708-720.
237. DeWitt MR, Chen P, Aschner M. Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations. Biochem Biophys Res Commun 2013; 432: 1-4.
238. Alam I, Gray AK, Chu K et al. Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone 2014; 59: 66-75.
239. Rajan I, Read R, Small, DL, Perrard J, Vogel P. An alternative splicing variant in Clcn7-/-mice prevents osteopetrosis but not neural and retinal degeneration. Vet Pathol 2011; 48: 663-675.
240. Kornak U, Kasper D, Bösl MR et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001; 104: 205-215.
241. Neutzsky-Wulff AV, Karsdal MA, Henriksen K. Characterization of the bone phenotype in ClC-7-deficient mice. Calcif Tissue Int 2008; 83: 425-437.
242. Vega RB, Matsuda K, Oh J et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004; 119: 555-566.
243. Arnold MA, Kim Y, Czubryt MP et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell 2007; 12: 377-389.
244. Rajan I, Savelieva KV, Ye GL et al. Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone development. PloS One 2009; 4: e6612.
245. van Wesenbeeck L, Odgren PR, Coxon FP et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest 2007; 117: 919-930.
246. del Fattore A, Fornari R, Van Wesenbeeck L et al. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing familyM(with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res 2008; 23: 380-391.
247. Vogel P, Read RW, Hansen GM et al. Congenital hydrocephalus in genetically engineered mice. Vet Pathol 2012; 49: 166-181.
248. Ueda Y, Yamaguchi R, Ikawa M et al. PGAP1 knock-out mice show otocephaly and male infertility. J Biol Chem 2007; 282: 30373-30380.
249. McKean DM, Niswander L. Defects in GPI biosynthesis perturb Cripto signaling during forebrain development in two new mouse models of holoprosencephaly. Biol Open 2012; 1: 874-883.
250. Park J, Kang SI, Lee SY et al. Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. J Biol Chem 2010; 285: 35029-35038.
251. Kondo Y, Inai Y, Sato Y et al. Senescence marker protein 30 functions as gluconolactonase in L-ascorbic acid biosynthesis, and its knockout mice are prone to scurvy. Proc Natl Acad Sci USA 2006; 103: 5723-5728.
252. MaedaN,Hagihara H, NakataYet al. Aortic wall damage in mice unable to synthesize ascorbic acid. Proc Natl Acad Sci USA 2000; 97: 841-846.
253. Kawai T, Nishikimi M, Ozawa T, Yagi K. A missense mutation of L-gulono-gamma-lactone oxidase causes the inability of scurvy-prone osteogenic disorder rats to synthesize L-ascorbic acid. J Biol Chem 1992; 267: 21973-21976.
254. Beamer WG, Rosen CJ, Bronson RT et al. Spontaneous fracture (sfx): a mouse genetic model of defective peripubertal bone formation. Bone 2000; 27: 619-626.
255. Mohan S, Kapoor A, Singgih A et al. Spontaneous fractures in themouse mutant sfx are caused by deletion of the gulonolactone oxidase gene, causing vitamin C deficiency. J Bone Miner Res 2005; 20: 1597-1610.
256. Gabbay KH, Bohren KM, Morello R, Bertin T, Liu J, Vogel P. Ascorbate synthesis pathway: dual role of ascorbate in bone homeostasis. J Biol Chem 2010; 285: 19510-19520.
257. Opsahl Vital S, Gaucher C, Bardet C et al. Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone 2012; 50: 989-997.
258. Foster BL, Ramnitz MS, Gafni RI et al. Rare bone diseases and their dental, oral, and craniofacial manifestations. J Dent Res 2014; 93: 7S-19S.
259. Al-Douri SM, Johnson DR. The development of the teeth of the microphthalmic (mi/mi) mouse. J Anat 1987; 153: 139-149.
260. Ma D, Zhang R, Sun Y et al. A novel role of periostin in postnatal tooth formation and mineralization. J Biol Chem 2011; 286: 4302-4309.
261. Kassai Y, Munne P, Hotta Y et al. Regulation of mammalian tooth cusp patterning by ectodin. Science 2005; 309: 2067-2070.
262. Ahn Y, Sanderson BW, Klein OD, Krumlauf R. Inhibition of Wnt signaling by Wise (Sostdc1) and negative feedback from Shh controls tooth number and patterning. Development 2010; 137: 3221-3231.
263. Miyata A, Baba O, Oda T, Ishikawa I, Takano Y. Diverse effects of c-src deficiency on molar tooth development and eruption inmice. Arch Histol Cytol 2007; 70: 63-78.
264. Savelieva KV, Zhao S, Pogorelov VM et al. Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PloS One 2008; 3: e3301.
265. Walther DJ, Peter JU, Bashammakh S et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76.
266. Liu Q, Yang Q, Sun W et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 2008; 325: 47-55.
267. Yadav VK, Oury F, Suda N et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009; 138: 976-989.
268. Shi ZC, Devasagayaraj A, Gu K et al. Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J Med Chem 2008; 51: 3684-3687.
269. Jin H, Cianchetta G, Devasagayaraj A et al. Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors. Bioorg Med Chem Lett 2009; 19: 5229-5232.
270. Cianchetta G, Stouch T, Yu W et al. Mechanism of inhibition of novel tryptophan hydroxylase inhibitors revealed by co-crystal structures and kinetic analysis. Curr Chem Genomics 2010; 4: 19-26.
271. Brown PM, Drossman DA, Wood AJ et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011; 141: 507-516.
272. Brommage R, Smith DD, Liu J, Yu W, Yang QM, Powell DR. Genetic disruption of brain serotonin content in mice produces leanness with hyperphagia and elevated physical activity but minimal skeletal changes. F1000Posters 2014; 5: 1029.
273. Wu J, Glimcher LH, Aliprantis AO. HCO3-/Cl-anion exchanger SLC4A2 is required for proper osteoclast differentiation and function. Proc Natl Acad Sci USA 2008; 105: 16934-16939.
274. Jansen ID, Mardones P, Lecanda F et al. Ae2(a,b)-deficient mice exhibit osteopetrosis of long bones but not of calvaria. FASEB J 2009; 23: 3470-3481.
275. Cortes VA, Curtis DE, Sukumaran S et al. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab 2009; 9: 165-176.
276. Vogel P, Read R, Hansen G et al. Pathology of congenital generalized lipodystrophy in Agpat2-/-mice. Vet Pathol 2011; 48: 642-654.
277. Settembre C, Annunziata I, Spampanato C et al. Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. Proc Natl Acad Sci USA 2007; 104: 4506-4511.
278. Settembre C, Arteaga-Solis E, McKee M et al. Proteoglycan desulfation determines the efficiency of chondrocyte autophagy and the extent of FGF signaling during endochondral ossification. Genes Dev 2008; 22: 2645-2650.
279. Kim JS, Ryoo ZY, Chun JS. Cytokine-like 1 (Cytl1) regulates the chondrogenesis of mesenchymal cells. J Biol Chem 2007; 282: 29359-29367.
280. Jeon J, Oh H, Lee G et al. Cytokine-like 1 knock-outmice (Cytl1-/-) show normal cartilage and bone development but exhibit augmented osteoarthritic cartilage destruction. J Biol Chem 2011; 286: 27206-27213.
281. Doetschman T. Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol 2009; 530: 423-433.
282. Matthaei KI. Identification of therapeutic drug targets through genetically manipulated mice: are we getting it right? Pharmacol Ther 2009; 123: 32-36.
283. Keane TM, Goodstadt L, Danecek P et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 2011; 477: 289-294.
284. Hofmann WE, Liu X, Bearden CM, Harper ME, Kozak LP. Effects of genetic background on thermoregulation and fatty acid-induced uncoupling of mitochondria in UCP1-deficient mice. J Biol Chem 2001; 276: 12460-12465.
285. Qiu J, Ogus S, Mounzih K, Ewart-TolandA, Chehab FF. Leptin-deficient mice backcrossed to the BALB/cJ genetic background have reduced adiposity, enhanced fertility, normal body temperature, and severe diabetes. Endocrinology 2001; 142: 3421-3425.
286. Toye AA, Lippiat JD, Proks P et al. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia 2005; 48: 675-686.
287. Freeman HC, Hugill A, Dear NT, Ashcroft FM, Cox RD. Deletion of nicotinamide nucleotide transhydrogenase: a new quantitive trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes 2006; 55: 2153-2156.
288. Scudamore CL. Integrating pathology into human disease modelling-how to eat the elephant. Dis Model Mech 2014; 7: 495-497.
289. Adissu HA, Estabel J, Sunter D et al. Histopathology reveals correlative and unique phenotypes in a high-throughput mouse phenotyping screen. Dis Model Mech 2014; 7: 515-524.
290. Prinz F, Schlange T, Asadullah K. Believe it or not: how much canwe rely on published data on potential drug targets? Nat Rev Drug Discov 2011; 10: 712.
291. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 2012; 483: 531-533.
292. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature 2014; 505: 612-613.
293. Boskey AL, van der Meulen MC, Wright TM. Guidelines for describing mouse skeletal phenotype. J Orthop Res 2003; 21: 1-5.
294. Manolagas SC, Kronenberg HM. Reproducibility of results in preclinical studies: a perspective from the bone field. J Bone Miner Res 2014; 29: 2131-2140.
295. Brommage R, Jeter-Jones S, Xiong WC, Champ R, Liu J. Mouse femoral neck architecture determined by microCT reflects skeletal architecture observed at other bone sites. J Bone Miner Res 2013; 28(Suppl 1): S347-S348.
296. Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol 2011; 347: 90-96.
297. Demay MB, MacDonald PN, Skorija K, Dowd DR, Cianferotti L, Cox M. Role of the vitamin D receptor in hair follicle biology. J Steroid Biochem Mol Biol 2007; 103: 344-346.
298. Barbaric I, Miller G, Dear TN. Appearances can be deceiving: phenotypes of knockout mice. Brief Funct Genomic Proteomic 2007; 6: 91-103.
299. Nagase S, Shimamune K, Shumiya S. Albumin-deficient rat mutant. Science 1979; 205: 590-591.
300. Kutuzova GD, Akhter S, Christakos S, Vanhooke J, Kimmel-Jehan C, Deluca HF. Calbindin D(9k) knockout mice are indistinguishable from wild-typemice in phenotype and serum calcium level. Proc Natl Acad Sci USA 2006; 103: 12377-12381.
301. Lee GS, Lee KY, Choi KC et al. Phenotype of a calbindin-D9k gene knockout is compensated for by the induction of other calcium transporter genes in amouse model. J BoneMiner Res 2007; 22: 1968-1978.
302. Akhter S, Kutuzova GD, Christakos S, DeLuca HF. Calbindin D9k is not required for 1,25-dihydroxyvitamin D3-mediated Ca21 absorption in small intestine. Arch Biochem Biophys 2007; 460: 227-232.
303. Kutuzova GD, Sundersingh F, Vaughan J et al. TRPV6 is not required for 1alpha,25-dihydroxyvitamin D3-induced intestinal calcium absorption in vivo. Proc Natl Acad Sci USA 2008; 105: 19655-19659.
304. Yngvadottir B, Xue Y, Searle S et al. A genome-wide survey of the prevalence and evolutionary forces acting on human nonsense SNPs. Am J Hum Genet 2009; 84: 224-234.
305. MacArthur DG, Balasubramanian S, Frankish A et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 2012; 335: 823-828.
306. Lim ET,Würtz P, Havulinna AS et al. Distribution and medical impact of loss-of-function variants in the finnish founder population. PLoS Genet 2014; 10: e1004494.
307. Maurin AC, Jousse C, Averous J et al. The GCN2 kinase biases feeding behavior to maintain amino acid homeostasis in omnivores. Cell Metab 2005; 1: 273-277.
308. Feldmann HM, Golozoubova V, Cannon B, Nedergaard J. UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality. Cell Metab 2009; 9: 203-209.
309. Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM. Iron status in mice carrying a targeted disruption of lactoferrin. Mol Cell Biol 2003; 23: 178-185.
310. Ye Q, Zheng Y, Fan S et al. Lactoferrin deficiency promotes colitisassociated colorectal dysplasia in mice. PloS One 2014; 9: e103298.
311. Safadi FF, Thornton P, Magiera H et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999; 103: 239-251.
312. Zella LA, Shevde NK, Hollis BW, Cooke NE, Pike JW. Vitamin Dbinding protein influences total circulating levels of 1,25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology 2008; 149: 3656-3667.
313. Booth FW, Laye MJ. Lack of adequate appreciation of physical exercise's complexities can pre-empt appropriate design and interpretation in scientific discovery. J Physiol 2009; 587: 5527-5539.
314. Adams D, Baldock R, Bhattacharya S et al. Bloomsbury report on mouse embryo phenotyping: recommendations from the IMPC workshop on embryonic lethal screening. DisModel Mech 2013; 6: 571-579.
315. Mohun T, Adams DJ, Baldock R et al. Deciphering the Mechanisms of Developmental Disorders (DMDD): a new programme for phenotyping embryonic lethal mice. Dis Model Mech 2013; 6: 562-566.
316. KitsiosGD, Tangri N, Castaldi PJ, Ioannidis JP. Laboratorymouse models for the human genome-wide associations. PLoS One 2010; 5: e13782.
317. Georgi B, Voight BF, Bucan M. From mouse to human: evolutionary genomics analysis of human orthologs of essential genes. PLoS Genet 2013; 9: e1003484.
318. Turgeon B, Meloche S. Interpreting neonatal lethal phenotypes inmouse mutants: insights into gene function and human diseases. Physiol Rev 2009; 89: 1-26.
319. Grimm D. Mouse genetics. A mouse for every gene. Science 2006; 312: 1862-1866.
320. Austin CP, Battey JF, Bradley A et al. The knockout mouse project. Nat Genet 2004; 36: 921-924.
321. Donahue LR, Hrabe de Angelis M, Hagn M et al. Centralized mouse repositories. Mamm Genome 2012; 23: 559-571.
322. Smith CM, Finger JH, Kadin JA, Richardson JE, Ringwald M. The gene expression database for mouse development (GXD): Putting developmental expression information at your fingertips. Dev Dyn 2014; 243: 1176-1186.
323. Matthaei KI. Genetically manipulated mice: a powerful tool with unsuspected caveats. J Physiol 2007; 582: 481-488.
324. Heffner CS, Herbert Pratt C, Babiuk RP et al. Supporting conditional mouse mutagenesis with a comprehensive cre characterization resource. Nat Commun 2012; 3: 1218.
325. Liu Y, Strecker S, Wang L et al. Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS One 2013; 8: e71318.
326. Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM, Long F et al. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One 2014; 9: e85161.
327. Brandon EP, Idzerda RL, McKnight GS. Knockouts. Targeting the mouse genome: a compendium of knockouts (Part I). Curr Biol 1995; 5: 625-634.
328. Kettleborough RN, Busch-Nentwich EM, Harvey SA et al. A systematic genome-wide analysis of zebrafish protein-coding gene function. Nature 2013; 496: 494-497.
329. The C. elegans Deletion Mutant Consortium. Large-scale screening for targeted knockouts in the Caenorhabditis elegans genome. G3 (Bethesda) 2012; 2: 1415-1425.
330. Giaever G, Nislow C. The yeast deletion collection: a decade of functional genomics. Genetics 2014; 197: 451-465.
331. Laulederkind SJ, Hayman GT, Wang SJ et al. The Rat Genome Database 2013 - data, tools and users. Brief Bioinform 2013; 14: 520-526.